期刊
ACTA OPHTHALMOLOGICA
卷 94, 期 3, 页码 E225-E230出版社
WILEY
DOI: 10.1111/aos.12721
关键词
best-corrected visual acuity; bevacizumab; branch retinal vein occlusion; central retinal thickness; fluorescein angiography; macular oedema; non-perfused areas; photocoagulation; vascular endothelial growth factor
PurposeTo investigate whether targeted retinal photocoagulation (TRP) of peripheral non-perfused areas (NPAs) could prevent the recurrence of macular oedema (ME) due to branch retinal vein occlusion (BRVO) after intravitreal bevacizumab injection (IVB). MethodsEyes received 1.25mg IVB only (IVB group) or combined with TRP (IVB+TRP group) of NPAs, more than 5 disc areas identified by fluorescein angiography in the patients with ME secondary to BRVO. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) determined by optical coherence tomography were measured every month for 6months. ResultsThirty-eight patients were enrolled and randomized to IVB group (n=19) and IVB+TRP group (n=19). Both groups showed similar thinning in CRT at 1week after IVB, IVB+TRP group maintained thinner retina at 2 (p=0.0072) and 3 (p=0.0086) months compared with IVB group in whom turned to thickened almost back to baseline at 3months. The number of reinjections in IVB group (1.580.69) was significantly greater (p=0.0025) than that in IVB+TRP group (0.83 +/- 0.62). BCVA significantly improved at 6month in IVB+TRP group (p=0.015), but not in IVB group. ConclusionTRP of NPAs reduced the amount of ME recurrence following IVB compared to IVB alone.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据